Provide customers with customized real world study solutions through retrospective multi-source data research, prospective observational research and a combination of different methods.
● Anti-coronavirus drug, using RWD synthetic arm to support FDA listing
● Helping overseas approved antitumor drugs to be exempted from RCT
in Hainan Lecheng Pioneer Zone
Our team brings together multidisciplinary experts in medical affairs, clinical research, Bioinformatics, Statistics, Health economics, Epidemiology, Data Science, and regulatory affairs. We have the unique domestic experience in using RWD synthetic arms to support FDA listing, and RWE to support drug indication expansion. At the same time, we have in-depth collaboration with Hainan Lecheng Medical Pioneer Zone to help overseas approved drugs and devices land in the Hainan Lecheng Medical Pioneer Zone, to realize the rapid listing of RWD instead of RCT in China. Collect post-marketing clinical drug data, convert RWD into RWE, help drugs realize application value and extend product life cycle.